dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Matito Ariza, Judit |
dc.contributor.author | Antunes de Melo Oliveira, Ana Mafalda |
dc.contributor.author | Wildiers, Hans |
dc.contributor.author | Brufksy, Adam M. |
dc.contributor.author | Waters, Simon |
dc.contributor.author | Vivancos Prellezo, Ana |
dc.contributor.author | Saura Manich, Cristina |
dc.date.accessioned | 2022-06-17T09:46:21Z |
dc.date.available | 2022-06-17T09:46:21Z |
dc.date.issued | 2021-11-01 |
dc.identifier.citation | Saura C, Matito J, Oliveira M, Wildiers H, Brufksy AM, Waters SH, et al. Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine vs Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer. Clin Cancer Res. 2021 Nov 1;27(21):5818–27. |
dc.identifier.issn | 1557-3265 |
dc.identifier.uri | https://hdl.handle.net/11351/7707 |
dc.description | Càncer de mama metastàtic; Biomarcadors; Capecitabina |
dc.description.sponsorship | This work was supported by Puma Biotechnology Inc. (no grant number is applicable). |
dc.language.iso | eng |
dc.publisher | American Association for Cancer Research |
dc.relation.ispartofseries | Clinical Cancer Research;27(21) |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Mama - Càncer - Tractament |
dc.subject | Quimioteràpia combinada |
dc.subject | Marcadors tumorals |
dc.subject.mesh | Breast Neoplasms |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Antineoplastic Combined Chemotherapy Protocols |
dc.subject.mesh | Biomarkers, Tumor |
dc.title | Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1158/1078-0432.CCR-21-1584 |
dc.subject.decs | neoplasias de la mama |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | protocolos de quimioterapia antineoplásica combinada |
dc.subject.decs | marcadores tumorales |
dc.relation.publishversion | https://doi.org/10.1158/1078-0432.CCR-21-1584 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Saura C, Oliveira M] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. SOLTI Innovative Breast Cancer Research, Barcelona, Spain. [Matito J] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Wildiers H] University Hospitals Leuven, Leuven, Belgium. [Brufksy AM] Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania. [Waters SH] Velindre Cancer Centre, Cardiff, Wales, United Kingdom. [Vivancos A] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. SOLTI Innovative Breast Cancer Research, Barcelona, Spain |
dc.identifier.pmid | 34380637 |
dc.identifier.wos | 000714656500013 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |